Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Incorporating Disease-Specific Molecular Targets into COPD Digital Twin Model for Innovative Drug Discovery

FY 2025-26

Summary
Chronic Obstructive Pulmonary Disease (COPD) is caused by damage to the lungs, making it difficult to breathe. It is one of the leading causes of death worldwide, with no cure. Most treatments focus on managing symptoms, which do not slow or stop the disease from worsening. With the recent rise of patient-specific treatments, COPD is shifting towards therapies that specifically target the underlying biological factors contributing to the disease. However, progress has been limited by ineffective preclinical cell-based and animal models of COPD that fail to replicate the full extent of the disease. This limitation poses a significant barrier to drug development, as it can lead to potential drugs failing in late-stage trials due to insufficient initial data about their effectiveness. To overcome this challenge, our team at UHN is leveraging artificial intelligence to build a computer model that predicts lung function based on physiological data. Building on this foundation, my MSc thesis aims to incorporate disease-specific biological information into the COPD computer model to evaluate the effectiveness of new therapies. Data will be collected from human lungs removed from the body for transplantation, both from organ donors and COPD patients receiving new lungs. By integrating biological data into the COPD computer model, it can more efficiently evaluate the effectiveness of new therapies during preclinical stages compared to traditional methods. This innovative approach aims to significantly reduce failure rates in late-stage drug development and accelerate the availability of new treatments for patients. Additionally, the computer model can be personalized for specific patient subtypes defined by their biological characteristics, allowing for tailored treatments.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572879
Name
Chowdhury Sumyia
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Incorporating Disease-Specific Molecular Targets into COPD Digital Twin Model for Innovative Drug Discovery
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Artificial Intelligence; Biologics; Chronic Obstructive Pulmonary Disease; Digital Twins; Disease Modelling; Drug Discovery; Ex Vivo Lung Perfusion; Ex Vivo Organ Perfusion; Personalized Medicine; Targeted Therapies
Abstract
Chronic Obstructive Pulmonary Disease (COPD) is caused by damage to the lungs, making it difficult to breathe. It is one of the leading causes of death worldwide, with no cure. Most treatments focus on managing symptoms, which do not slow or stop the disease from worsening. With the recent rise of patient-specific treatments, COPD is shifting towards therapies that specifically target the underlying biological factors contributing to the disease. However, progress has been limited by ineffective preclinical cell-based and animal models of COPD that fail to replicate the full extent of the disease. This limitation poses a significant barrier to drug development, as it can lead to potential drugs failing in late-stage trials due to insufficient initial data about their effectiveness. To overcome this challenge, our team at UHN is leveraging artificial intelligence to build a computer model that predicts lung function based on physiological data. Building on this foundation, my MSc thesis aims to incorporate disease-specific biological information into the COPD computer model to evaluate the effectiveness of new therapies. Data will be collected from human lungs removed from the body for transplantation, both from organ donors and COPD patients receiving new lungs. By integrating biological data into the COPD computer model, it can more efficiently evaluate the effectiveness of new therapies during preclinical stages compared to traditional methods. This innovative approach aims to significantly reduce failure rates in late-stage drug development and accelerate the availability of new treatments for patients. Additionally, the computer model can be personalized for specific patient subtypes defined by their biological characteristics, allowing for tailored treatments.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chowdhury, Sumyia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~